Is Canakinumab Safe During Pregnancy? New Insights from Three Cases in Slovakia

Is Canakinumab Safe During Pregnancy? New Insights from Three Cases in Slovakia

<b>Background and Objectives</b>: Canakinumab, a human recombinant monoclonal antibody against interleukin-1ß (IL-1ß), is indicated for the treatment of selected autoinflammatory periodic fever syndromes and rheumatic diseases. Data on its use during pregnancy remain limited and all are...

Full description

Saved in:

Bibliographic Details
Main Authors:	Branislav Slenker, Katarina Hrubiskova, Lenka Kapustova, Anna Bobcakova, Juraj Ondris, Milos Jesenak
Format:	Article
Language:	English
Published:	MDPI AG 2025-04-01
Series:	Biologics
Subjects:	autoinflammatory diseases canakinumab inflammation interleukin-1 pregnancy safety
Online Access:	https://www.mdpi.com/2673-8449/5/2/12
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis
by: T. V. Sleptsova, et al.
Published: (2016-06-01)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016-11-01)

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series
by: S. O. Salugina, et al.
Published: (2016-02-01)

Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01)

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
by: Mustafa Çakan, et al.
Published: (2020-04-01)

Therapy with canakinumab for adult-onset still's disease
by: E. L. Nasonov
Published: (2019-04-01)

A familial case of Muckle-Wells syndrome in a Russian population: The first successes of therapy with the interleukin 1 inhibitor canakinumab
by: S. O. Salugina, et al.
Published: (2015-03-01)

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry
by: Prasad T. Oommen, et al.
Published: (2024-12-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015-04-01)

Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review
by: Howard Jie Yang, et al.
Published: (2025-12-01)

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system
by: Hao Liu, et al.
Published: (2025-04-01)

Treating TRAPS Syndrome with a Previously Undescribed TNF α Gene Receptor Mutation Successfully with Canakinumab
by: T. V. Sleptsova, et al.
Published: (2016-11-01)

The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01)

Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used
by: M. S. Eliseev, et al.
Published: (2015-06-01)

Schnitzler Syndrome: An Under-Recognised Cause of Pyrexia of Unknown Origin
by: Dennis Tin Ho Chan, et al.
Published: (2025-07-01)

Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis
by: Ekaterina I. Alexeeva, et al.
Published: (2017-06-01)

EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
by: Maksim Sergeyevna Eliseev, et al.
Published: (2014-03-01)

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-09-01)

Low-penetrance R92Q (p.Arg121Gln) mutation in the <i>TNFRSF1A</i> gene: the significance and variants of phenotypes. Successful experience with the interleukin-1 inhibitor canakinumab in a female patient, who is a carrier of R92Q mutation with a severe TRAPS phenotype
by: E. S. Fedorov, et al.
Published: (2020-09-01)

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study
by: Michel Moutschen, et al.
Published: (2025-05-01)

Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case
by: Elena A. Ligostaeva, et al.
Published: (2020-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report
by: Maria Grazia Massaro, et al.
Published: (2020-08-01)

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014-03-01)

The role of interleukin 1 in the development of human diseases
by: E. L. Nasonov
Published: (2019-04-01)

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014-05-01)

Experience with canakinumab in a patient with gout and IgA nephropathy
by: E. V. Ilyinykh, et al.
Published: (2019-09-01)

Assessing Efficacy of Interleukin-1 Blockade in Patients with Alcoholic Hepatitis: A Comprehensive Systematic Review of Emerging Evidence
by: Shree Rath, et al.
Published: (2025-07-01)

AUTOINFLAMMATORY DISEASES IN RHEUMATOLOGY: RUSSIAN EXPERIENCE
by: S. O. Salugina, et al.
Published: (2016-07-01)

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
by: Armando Santoro, et al.
Published: (2024-10-01)

A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
by: R. R. Samigullina, et al.
Published: (2019-03-01)

Diagnosis, management, and monitoring of interleukin-1 mediated diseases in Central and Eastern Europe: real-world data
by: Marija Jelusic, et al.
Published: (2025-05-01)

Role of interleukin 1 in the development of atherosclerosis
by: E. L. Nasonov, et al.
Published: (2019-04-01)

ANTI-INFLAMMATORY THERAPY FOR ATHEROSCLEROSIS: CONTRIBUTION TO AND LESSONS OF RHEUMATOLOGY
by: E. L. Nasonov, et al.
Published: (2017-10-01)

Adult Still's disease: New horizons
by: E. L. Nasonov, et al.
Published: (2021-12-01)

The Experience of Using a Combination of Febuxostat and Canakinumab in Tophaceous Gout Complicated by Chronic Kidney Disease in a Teenage Patient: A Case Study
by: Maria I. Kaleda, et al.
Published: (2018-12-01)

ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES
by: E. L. Nasonov, et al.
Published: (2016-03-01)

Autoinflammatory diseases. Part 3: NLRP and NLRC inflammasomopathies. Biologic therapies for inflammasomopathies
by: O.V. Shvaratska, et al.
Published: (2025-04-01)

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)
by: E. L. Nasonov, et al.
Published: (2022-07-01)

Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout
by: M. S. Eliseev, et al.
Published: (2016-03-01)